Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C4221008 - Encorafenib + Binimetinib in BRAFV600-mutant NSCLC
2024-515929-28-00Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of encorafenib and binimetinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Started Aug 2019; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515929-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515929-28-00.